Skip to main content
SpringerLink
Log in

Imiquimod

In Superficial Basal Cell Carcinoma

  • Adis Drug Profile
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

▴ Imiquimod, available as a 5% cream, is a new topical treatment for adults with superficial basal cell carcinoma (BCC). The exact mechanism of action of imiquimod in superficial BCC is unknown. Imiquimod may act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells.

▴ Topical imiquimod 5% cream effectively increased clinical and histologic clearance of single superficial BCC lesions compared with vehicle in patients enrolled in two large, well designed trials. Patients applied imiquimod five or seven times per week or vehicle for 6 weeks, and the composite clearance rates at 12 weeks post-treatment for the corresponding treatment groups were 75%, 73%, and 2%, respectively.

▴ In a trial investigating the long-term efficacy of imiquimod 5% cream following application five times per week for 6 weeks, a clinical clearance rate of 90% was reported at the initial 12-week post-treatment examination. The estimated rate of clinical clearance at the 1-year follow-up visit was 84%.

▴ Application site and local skin reactions were the most common adverse events reported by imiquimod recipients. The severity of erythema, erosion, and scabbing/crusting correlated positively with the composite and histologic response rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Salasche S. Imiquimod 5% cream: a new treatment option for basal cell carcinoma. Int J Dermatol. 2002 May; 41 Suppl. 1: 16–20

    Article  PubMed  CAS  Google Scholar 

  2. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003 Oct 4; 327 (7418): 794–8

    Article  PubMed  CAS  Google Scholar 

  3. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol. 1999 Sep; 141 (3): 415–23

    Article  PubMed  CAS  Google Scholar 

  4. Dummer R, Urosevic M, Kempf W, et al. Imiquimod in basal cell carcinoma: how does it work?. Br J Dermatol. 2003 Nov; 149 Suppl. 66: 57–8

    Article  PubMed  CAS  Google Scholar 

  5. Urosevic M, Oberholzer PA, Maier T, et al. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferona. Clin Cancer Res. 2004 Aug 1; 10 (15): 4959–70

    Article  PubMed  CAS  Google Scholar 

  6. Sullivan TP, Dearaujo T, Vincek V, et al. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg. 2003 Dec; 29 (12): 1181–6

    Article  PubMed  Google Scholar 

  7. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003 Oct; 139 (10): 1325–32

    Article  PubMed  CAS  Google Scholar 

  8. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bel-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol. 2004 Sep; 151 (3): 656–62

    Article  PubMed  CAS  Google Scholar 

  9. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Just. 2003 Aug 6; 95 (15): 1138–49

    Article  Google Scholar 

  10. Alomar Muntanola A, Vidal D, Matias-Gum X. Effect of topical application of imiquimod 5% on the apoptosis of basal cell carcinomas. Ann Dermatol Venereol. 2002 Jul; 129 Suppl.: S773

    Google Scholar 

  11. Kooy AJ, Tank B, Vuzevski VD, et al. Expression of interferon-,γ receptors and interferon-,γ-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN-γR and shedding of ICAM-1 as a means to escape immune surveillance. J Pathol. 1998 Feb; 184 (2): 169–76

    Article  PubMed  CAS  Google Scholar 

  12. Berman B, Sullivan T, De Araujo T, et al. Evaluation of superficial basal cell carcinomas for imiquimod treatment-induced apoptosis [abstract no. P2063]. Ann Dermatol Venereol. 2002; 129 Suppl.: S774

    Google Scholar 

  13. Berman B, Sullivan T, De Araujo T, et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol. 2003 Nov; 149 Suppl. 66: 59–61

    Article  PubMed  CAS  Google Scholar 

  14. Tygum KI, Smith SL, Myers JA, et al. Percutaneous penetration of [14C] imiquimod from a single application of cream. Pharm Res. 1995; 12 Suppl.: 277

    Google Scholar 

  15. Owens ML, Tygum KI, Senta TA, et al. A safety assessment of topical imiquimod [abstract]. Australas J Dermatol. 1997; 38 Suppl. 2: 269

    Google Scholar 

  16. 3M Pharmaceuticals. Aldara™ (imiquimod): US prescribing information. St Paul (MN). 2004

    Google Scholar 

  17. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004 May; 50 (5): 722–33

    Article  PubMed  Google Scholar 

  18. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-con-trolled study. J Am Acad Dermatol. 2002 Sep; 47: 390–8

    Article  PubMed  Google Scholar 

  19. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. The Australasian Multicentre Trial Group. J Am Acad Dermatol. 2001 May; 44: 807–13

    Article  PubMed  CAS  Google Scholar 

  20. Marks R, Owens M, Walters SA. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas [letter]. Arch Dermatol. 2004 Oct; 140 (10): 1284–5

    Article  PubMed  Google Scholar 

  21. Freeman M, Siller G, Edwards S, et al. Imiquimod 5% cream in the treatment of multiple superficial basal cell carcinoma. J Am Acad Dermatol. 2004 Mar; 50 (3 Suppl.): 7 plus poster presented at the American Academy of Dermatology 62nd Annual Meeting, February 6–11, 2004, Washington, DC [abstract no. P27]

    Article  Google Scholar 

  22. Gollnick H, Barona CG, Frank R, et al. Efficacy by clinical evaluation of imiquimod 5% cream in the treatment of superficial basal cell carcinoma: initial results from an ongoing, long-term follow-up study in Europe. J Am Acad Dermatol. 2004 Mar; 50 (3 Suppl.): 124 plus poster presented at the American Academy of Dermatology 62nd Annual Meeting, February 6–11, 2004, Washington, DC [abstract no. P480]

    Article  Google Scholar 

  23. Gebauer K, Quirk C, De’Ambrosis B, et al. Efficacy by clinical evaluation of imiquimod 5% cream in the treatment of superficial basal cell carcinoma: initial results from an ongoing, long-term follow-up study in Australia and New Zealand. J Am Acad Dermatol. 2004 Mar; 50 (3 Suppl.): 124 plus poster presented at the American Academy of Dermatology 62nd Annual Meeting, February 6–11, 2004, Washington, DC [abstract no. P481]

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 770 Township Line Road, Suite 300, Yardley, 19067, USA

    Vicki Oldfield, Gillian M. Keating & Caroline M. Perry

Authors
  1. Vicki Oldfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vicki Oldfield.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oldfield, V., Keating, G.M. & Perry, C.M. Imiquimod. Am J Clin Dermatol 6, 195–200 (2005). https://doi.org/10.2165/00128071-200506030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200506030-00006

Keywords

Search

Navigation